Logo image of TGTX

TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX - Nasdaq - US88322Q1085 - Common Stock - Currency: USD

31.7  -1.66 (-4.98%)

After market: 31.6683 -0.03 (-0.1%)

Fundamental Rating

4

Overall TGTX gets a fundamental rating of 4 out of 10. We evaluated TGTX against 572 industry peers in the Biotechnology industry. The financial health of TGTX is average, but there are quite some concerns on its profitability. TGTX is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year TGTX has reported negative net income.
In the past year TGTX has reported a negative cash flow from operations.
In the past 5 years TGTX reported 4 times negative net income.
TGTX had a negative operating cash flow in each of the past 5 years.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M -300M

1.2 Ratios

The Return On Assets of TGTX (-2.45%) is better than 90.62% of its industry peers.
With an excellent Return On Equity value of -7.48%, TGTX belongs to the best of the industry, outperforming 91.15% of the companies in the same industry.
Industry RankSector Rank
ROA -2.45%
ROE -7.48%
ROIC N/A
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

TGTX has a better Gross Margin (88.32%) than 91.33% of its industry peers.
The Profit Margin and Operating Margin are not available for TGTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.32%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

4

2. Health

2.1 Basic Checks

TGTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TGTX has been increased compared to 1 year ago.
Compared to 5 years ago, TGTX has more shares outstanding
Compared to 1 year ago, TGTX has an improved debt to assets ratio.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

TGTX has an Altman-Z score of 5.57. This indicates that TGTX is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 5.57, TGTX belongs to the top of the industry, outperforming 81.95% of the companies in the same industry.
TGTX has a Debt/Equity ratio of 1.27. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of TGTX (1.27) is worse than 80.35% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Altman-Z 5.57
ROIC/WACCN/A
WACC10.78%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M

2.3 Liquidity

TGTX has a Current Ratio of 4.59. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
TGTX has a Current ratio (4.59) which is comparable to the rest of the industry.
A Quick Ratio of 3.91 indicates that TGTX has no problem at all paying its short term obligations.
The Quick ratio of TGTX (3.91) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.59
Quick Ratio 3.91
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 60.71% over the past year.
The Revenue has grown by 39.51% in the past year. This is a very strong growth!
Measured over the past years, TGTX shows a very strong growth in Revenue. The Revenue has been growing by 335.01% on average per year.
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%

3.2 Future

The Earnings Per Share is expected to grow by 222.31% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 43.05% on average over the next years. This is a very strong growth
EPS Next Y1366.25%
EPS Next 2Y891.48%
EPS Next 3Y486.05%
EPS Next 5Y222.31%
Revenue Next Year42.85%
Revenue Next 2Y54.4%
Revenue Next 3Y48.91%
Revenue Next 5Y43.05%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B 2B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 2 -2 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

TGTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
The Price/Forward Earnings ratio is 32.25, which means the current valuation is very expensive for TGTX.
Based on the Price/Forward Earnings ratio, TGTX is valued cheaply inside the industry as 92.92% of the companies are valued more expensively.
TGTX's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 92.56.
Industry RankSector Rank
PE N/A
Fwd PE 32.25
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -100 -200

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1 1.5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as TGTX's earnings are expected to grow with 486.05% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y891.48%
EPS Next 3Y486.05%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for TGTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TG THERAPEUTICS INC

NASDAQ:TGTX (1/31/2025, 7:27:00 PM)

After market: 31.6683 -0.03 (-0.1%)

31.7

-1.66 (-4.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)N/A N/A
Inst Owners61.18%
Inst Owner Change-0.12%
Ins Owners9.59%
Ins Owner Change-0.34%
Market Cap4.93B
Analysts81.33
Price Target41.57 (31.14%)
Short Float %18.45%
Short Ratio8.41
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)76.13%
Min EPS beat(2)-33.53%
Max EPS beat(2)185.79%
EPS beat(4)2
Avg EPS beat(4)16.52%
Min EPS beat(4)-92.18%
Max EPS beat(4)185.79%
EPS beat(8)4
Avg EPS beat(8)66.09%
EPS beat(12)7
Avg EPS beat(12)50.32%
EPS beat(16)7
Avg EPS beat(16)32.35%
Revenue beat(2)2
Avg Revenue beat(2)4.98%
Min Revenue beat(2)0.65%
Max Revenue beat(2)9.31%
Revenue beat(4)4
Avg Revenue beat(4)7.88%
Min Revenue beat(4)0.65%
Max Revenue beat(4)13.96%
Revenue beat(8)6
Avg Revenue beat(8)37.84%
Revenue beat(12)8
Avg Revenue beat(12)33.32%
Revenue beat(16)9
Avg Revenue beat(16)14.34%
PT rev (1m)5.39%
PT rev (3m)18.85%
EPS NQ rev (1m)0%
EPS NQ rev (3m)1521.01%
EPS NY rev (1m)0%
EPS NY rev (3m)-2.54%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)27.49%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.54%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 32.25
P/S 18.64
P/FCF N/A
P/OCF N/A
P/B 25.68
P/tB 25.68
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)0.98
Fwd EY3.1%
FCF(TTM)-0.18
FCFYN/A
OCF(TTM)-0.18
OCFYN/A
SpS1.7
BVpS1.23
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.45%
ROE -7.48%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.32%
FCFM N/A
ROA(3y)-63.44%
ROA(5y)-68.2%
ROE(3y)-159.11%
ROE(5y)-195.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity 1.27
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 24%
Cap/Sales 0.01%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.59
Quick Ratio 3.91
Altman-Z 5.57
F-Score2
WACC10.78%
ROIC/WACCN/A
Cap/Depr(3y)48.73%
Cap/Depr(5y)100.24%
Cap/Sales(3y)2.11%
Cap/Sales(5y)66.6%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)60.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-97.26%
EPS Next Y1366.25%
EPS Next 2Y891.48%
EPS Next 3Y486.05%
EPS Next 5Y222.31%
Revenue 1Y (TTM)39.51%
Revenue growth 3Y1059.22%
Revenue growth 5Y335.01%
Sales Q2Q%-49.41%
Revenue Next Year42.85%
Revenue Next 2Y54.4%
Revenue Next 3Y48.91%
Revenue Next 5Y43.05%
EBIT growth 1Y97.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year280.46%
EBIT Next 3Y123.33%
EBIT Next 5YN/A
FCF growth 1Y88.25%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y88.26%
OCF growth 3YN/A
OCF growth 5YN/A